Skip to main content
Premium Trial:

Request an Annual Quote

NanoString Raises $4.3M to Commercialize ISB s Genetic Analysis Technology

NEW YORK, Aug. 11 (GenomeWeb News) - NanoString Technologies said today that it has secured $4.3 million in an investment round led by OVP Venture Partners and Draper Fisher Jurvetson.

 

NanoString said it plans to use the funding to accelerate development of its technology platform, a single-molecule bar-coding system developed at the Institute for Systems Biology for use in gene expression analysis.

 

NanoString has an exclusive license with ISB for rights to the technology, which was developed by Krassen Dimitrov, chief scientific officer of NanoString and former director of microarrays at ISB. The company said it anticipates the technology to be as much as 100,000 times more sensitive than a DNA microarray.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.